Also referenced as: TZ, GIP/GLP-1 dual receptor agonist
A literature-led overview of GLP-2 (TR) — what has actually been measured in the published record, what remains unknown, and how research-grade material is characterised.
5 min read · Literature review · Updated 2026
Research-grade GLP-2 (TR) vials — ≥99% HPLC purity, lot-matched COA on request, from $27.99.
Shop GLP-2 (TR)A dual GIP/GLP-1 receptor agonist built on a GIP backbone, commonly used as the comparator between single-receptor agonists and newer multi-receptor candidates.
Research material is supplied as a lyophilised powder in a sealed vial, reconstituted with bacteriostatic water immediately before use and characterised by reverse-phase HPLC with identity confirmed by mass spectrometry. The published record for GLP-2 (TR) is dominated by published clinical and preclinical sources, which is the most important caveat when reading any summary of its reported effects.
The areas below summarise what published work has actually measured. Each is an observation reported in the cited literature — not a claimed outcome, and not a statement of efficacy in humans.
Metabolic signalling research
Randomised human literature has investigated dual incretin receptor engagement and glycaemic and body-weight endpoints.
Receptor-selectivity research
In-vitro work has characterised relative GIP versus GLP-1 receptor potency and biased signalling profiles.
Mechanistic descriptions of GLP-2 (TR) in the literature centre on the pathways below. Pathway attributions should be read as proposed rather than settled.
Dual GIP/GLP-1 receptor agonism
Reported to activate both incretin receptors with distinct potency ratios described in receptor pharmacology literature. Pathway noted in the literature: GIPR + GLP-1R → Gs → cAMP.
Safety observations are drawn from published clinical literature and do not establish safety for human use outside those trials.
Reported observations in the available literature include: Gastrointestinal adverse events reported most frequently. These are reports from the study conditions described, not an established adverse-event profile.
Open data gaps: long-term data continue to accumulate. Peptide Lounge does not publish dosing or administration guidance for any compound, and this material is not for human or veterinary use.
Every GLP-2 (TR) lot is released at ≥99% purity by RP-HPLC with identity confirmed by ESI-MS, and a lot-matched certificate of analysis is available on request rather than a generic sample document.
Vials ship lyophilised and sealed, and are stable at ambient temperature during transit. Store unreconstituted vials refrigerated and protected from light; once reconstituted, keep refrigerated and treat the solution as short-dated. Experimental concentrations must be determined by the researcher from the peer-reviewed literature under their own institutional protocol.
GLP-2 (TR) is stocked as single-compound vials in 10mg, 20mg, 30mg, 60mg, with volume pricing applied automatically to multi-vial orders. Free bacteriostatic water and research supplies are included on qualifying orders.
Published work describes metabolic signalling research, receptor-selectivity research. Some of this record includes human data, but findings should still be read in the context of each study's design.
Reported observations include Gastrointestinal adverse events reported most frequently. Beyond these, long-term data continue to accumulate remain open.
No. GLP-2 (TR) supplied by Peptide Lounge is a laboratory reagent for in-vitro and laboratory research only. It is not an approved drug and is not for human or veterinary use.
Store lyophilised vials refrigerated and protected from light. Reconstitute with bacteriostatic water immediately before use and keep the resulting solution refrigerated. Vials remain stable at ambient temperature during shipping.
Request the lot-matched certificate of analysis for the batch you received. It reports RP-HPLC purity (≥99%) and ESI-MS identity confirmation for that specific lot.
Randomised human literature has investigated dual incretin receptor engagement and glycaemic and body-weight endpoints.
In-vitro work has characterised relative GIP versus GLP-1 receptor potency and biased signalling profiles.
Reported to activate both incretin receptors with distinct potency ratios described in receptor pharmacology literature.
GIPR + GLP-1R → Gs → cAMP
Jastreboff AM, Aronne LJ, Ahmad NN et al.
72-week randomised placebo-controlled phase 3 trial of a dual incretin receptor agonist.
Safety observations are drawn from published clinical literature and do not establish safety for human use outside those trials.
Known data gaps: Long-term data continue to accumulate.
For Research Use Only
All products listed are supplied strictly as laboratory reagents for in-vitro research and analytical work conducted by qualified professionals. They are not drugs, foods, cosmetics or medical devices, and must not be administered to humans or animals. No product on this site is approved by the FDA for human use.
Research Use Only: Products are sold strictly for laboratory research and educational purposes only. Not for human consumption, veterinary use, food use, cosmetic use, or therapeutic application. Products are not intended to diagnose, treat, cure, or prevent any disease.
